Abstract
The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a reasonable understanding of the structural requirements needed for a molecule to bind to MDM2 and successfully inhibit the p53/MDM2 interaction. The current review summarizes the binding characteristics of the different disclosed small molecules for inhibition of MDM2 with a co-crystal structure. Synthetic access to these compounds as well as their derivatives are described in detail.
Keywords: p53, MDM2, HDM2, protein protein interactions, small molecule inhibitors, negative regulator, cancer, Angstrom level, p53/MDM2 interaction, derivatives.
Current Pharmaceutical Design
Title:P53 Mdm2 Inhibitors
Volume: 18 Issue: 30
Author(s): Kareem Khoury and Alex Domling
Affiliation:
Keywords: p53, MDM2, HDM2, protein protein interactions, small molecule inhibitors, negative regulator, cancer, Angstrom level, p53/MDM2 interaction, derivatives.
Abstract: The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a reasonable understanding of the structural requirements needed for a molecule to bind to MDM2 and successfully inhibit the p53/MDM2 interaction. The current review summarizes the binding characteristics of the different disclosed small molecules for inhibition of MDM2 with a co-crystal structure. Synthetic access to these compounds as well as their derivatives are described in detail.
Export Options
About this article
Cite this article as:
Khoury Kareem and Domling Alex, P53 Mdm2 Inhibitors, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651580
DOI https://dx.doi.org/10.2174/138161212802651580 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging The Metabolism of Anthocyanins
Current Drug Metabolism iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Protection Mechanisms Against Aβ42 Aggregation
Current Alzheimer Research Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Nose to Brain Delivery: New Trends in Amphiphile-Based “Soft” Nanocarriers
Current Pharmaceutical Design Osteopontin as a Potential Therapeutic Target for Ischemic Stroke
Current Drug Delivery MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Accuracy of Magnetic Resonance Spectroscopy in Discrimination of Neoplastic and Non-Neoplastic Brain Lesions
Current Medical Imaging Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Autophagy: A Major Target of Cadmium Nephrotoxicity
Current Chemical Biology Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research